CN104306807A - Compound preparation for treating advanced lung cancer and preparing method thereof - Google Patents
Compound preparation for treating advanced lung cancer and preparing method thereof Download PDFInfo
- Publication number
- CN104306807A CN104306807A CN201410660448.6A CN201410660448A CN104306807A CN 104306807 A CN104306807 A CN 104306807A CN 201410660448 A CN201410660448 A CN 201410660448A CN 104306807 A CN104306807 A CN 104306807A
- Authority
- CN
- China
- Prior art keywords
- parts
- lung cancer
- herba
- compound preparation
- advanced lung
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a compound preparation for treating advanced lung cancer. The compound preparation comprises, by weight, the components of 10-15 parts of Codonopsis pilosula, 15-30 parts of Oldenlandia diffusa, 15-30 parts of nightshade, 15-30 parts of salvia chinensis, 15-30 parts of edible tulip, 15-30 parts of coffee senna, 15-30 parts of Rubus parvifolius, 15-30 parts of duchesnea, 1-3 parts of Chinese yew and 5-10 parts of liquorice. The compound preparation for treating advanced lung cancer has double effects of healthy energy strengthening and anticancer performance. The invention further provides a preparing method of the compound preparation for treating advanced lung cancer. The technology is simple, product quality is stable, and the invention further provides an application of the compound preparation for treating advanced lung cancer in advanced lung cancer anticancer medicine.
Description
Technical field
The present invention relates to the field of Chinese medicines, refer to a kind of compound preparation for the treatment of advanced lung cancer especially, the invention still further relates to a kind of preparation method for the treatment of the compound preparation of advanced lung cancer, the invention still further relates to a kind of compound preparation for the treatment of advanced lung cancer and preparing the application in advanced lung cancer medicine.
Background technology
Pulmonary carcinoma is one of common malignant tumor in the whole world, for the current mankind are because of the main cause of cancer mortality, is endanger one of maximum malignant tumor to human health and life.According to statistics, the number of the infected of global pulmonary carcinoma in 2011 is 16.08 ten thousand people.At present for advanced Non-small cell lung, combined chemotherapy based on platinum class is considered to its standard regimens, but general curative effect display median survival time was less than 10 months, seldom had the life span of patient more than 2 years, clinical efficacy reaches " bottleneck " phase, and toxicity is large.In recent years, targeted drug appears at the existence bottleneck breaching chemotherapy to a certain extent, but also there is many problems in targeted drug, as being only applicable to specific crowd, as EGFR-TKI (epidermal growth factor tyrosinase inhibitor) is only applicable to the patient of EGFR sudden change, there is certain toxicity and the problem such as expensive.
In China, most of tumor patient accepts Chinese medicine.Chinese medicine to be combined with operation, radiotherapy, chemotherapy, thermotherapy, Biotherapeutics and targeted drug etc. to combine and all to demonstrate some superiority.
The Chinese patent medicine or the Chinese medicine compound that are used for the treatment of advanced lung cancer are at present of a great variety, but the ratio that most of Chinese patent medicine contains anticancer herbal drug is on the low side, or only have anticancer herbal drug, and cause therapeutic effect to show single, effect is not good.
Chinese patent " Chinese medicinal active ingredient compound preparation for the treatment of pulmonary carcinoma and preparation method thereof ", patent No. CN 103054881A, disclose a kind of Chinese medicinal active ingredient compound preparation for the treatment of pulmonary carcinoma: paclitaxel 1 ~ 3 part, cinobufagin 1 ~ 3 part, triptolide 1 ~ 3 part, this formula has the effect that kind of active anticancer is high, anticancer spectrum is wide.
In recent years, along with the research to pulmonary carcinoma, also there is the Chinese medicine preparation patent application of many treatment pulmonary carcinoma also open, constantly improve the effect for the treatment of by Chinese herbs pulmonary carcinoma, Chinese patent " a kind of compound Chinese medicinal preparation for the treatment of nonsmall-cell lung cancer and preparation method thereof ", patent No. CN 102861284A, disclose a kind of compound Chinese medicinal preparation for the treatment of nonsmall-cell lung cancer, comprise each component composition of following weight portion: Radix Astragali 1-10 part, Radix Pseudostellariae 1-10 part, Rhizoma Curcumae Longae 1-10 part, Radix Curcumae 1-10 part, 1 Concha Ostreae 1-10 part, Nidus Vespae 1-10 part, Spica Prunellae 1-10 part, Herba Hedyotidis Diffusae 1-10 part, this prescription is by the Radix Astragali, Radix Pseudostellariae, Rhizoma Curcumae Longae, Radix Curcumae, Concha Ostreae, Nidus Vespae, Spica Prunellae, the compositions such as Herba Hedyotidis Diffusae, to reach collection righting, removing toxic substances, the effect that blood stasis dispelling three kinds of TCM on Tumor rules are integrated, three methods are share, can right supporting anticancer, again can prevention of recurrence transfer.
For many years, " dialectical+differential diagnosis of diseases+suit the medicine to the illness " treatment is guideline to inventor's Study of Traditional Chinese Medicine treatment pulmonary carcinoma, understands the common TCM Syndrome Type of pulmonary carcinoma by Epidemiological study, in conjunction with its pattern of syndrome, for guiding theory, draw up corresponding prescription with " disease combination ", and collected by case for many years and analyze, and study, learn, in cases of lung cancer in recent years, qi-asthenia phlegm wet type is maximum, accounting for 76.3%, is secondly type of deficiency of both QI and YIN, the scorchingly hot type of the deficiency of YIN and qi stagnation and blood stasis type; Carry out analysis to patients with terminal pattern of syndrome to find, qi-asthenia phlegm wet type is maximum, is secondly type of deficiency of both QI and YIN, qi stagnation and blood stasis type, the scorchingly hot type of the deficiency of YIN and extreme noxious heat.The TCM Syndrome Type of advanced lung cancer is based on qi-asthenia phlegm wet type, and it is asthenia of pulmonosplenic qi, and pyretic toxicity, phlegm-damp, blood stasis are mark.
According to above-mentioned dialectical Thoughts, the TCM Syndrome Type of advanced lung cancer is distinguished, thus draw up the prescription meeting this pattern of syndrome targetedly, reach effect of right supporting anticancer, become the important and difficult issues of research.
Summary of the invention
The present invention proposes a kind of compound preparation for the treatment of advanced lung cancer, and from organic conception, determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, dialectically combines with differential diagnosis of diseases, and reach both containing righting class Chinese herbal medicine, again containing anticancer class Chinese herbal medicine, the two has combined righting and antitumaous effect.
The invention allows for a kind of preparation method for the treatment of the compound preparation of advanced lung cancer, easy to prepare, constant product quality.
The invention allows for a kind of application for the treatment of the compound preparation of advanced lung cancer.
The present invention realizes in the following way:
A kind of compound preparation for the treatment of advanced lung cancer, comprise each component of following weight portion: Radix Codonopsis 10-15 part, Herba Hedyotidis Diffusae 15-30 part, Herba Solani Nigri 15-30 part, Herba Salviae Chinensis 15-30 part, Pseudobulbus Cremastrae Seu Pleiones 15-30 part, Herba cassiae occidentalis 15-30 part, Rubus Parvifolius L. 15-30 part, Herba Duchesneae Indicae 15-30 part, Ramulus et folium taxi cuspidatae 1-3 part, Radix Glycyrrhizae 5-10 part.
For improving effect further, the adjustment that inventor is optimized formula, after adjustment is: Radix Codonopsis 10-15 part, Rhizoma Atractylodis Macrocephalae 10-15 part, Radix Astragali 15-30 part, Herba Hedyotidis Diffusae 15-30 part, Herba Solani Nigri 15-30 part, Herba Salviae Chinensis 15-30 part, Pseudobulbus Cremastrae Seu Pleiones 15-30 part, fry Semen Coicis 15-30 part, Herba cassiae occidentalis 15-30 part, Rubus Parvifolius L. 15-30 part, Herba Duchesneae Indicae 15-30 part, Ramulus et folium taxi cuspidatae 1-3 part, Radix Glycyrrhizae 5-10 part.
What be more preferably is: Radix Codonopsis 15 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, the Radix Astragali 30 parts, Herba Hedyotidis Diffusae 30 parts, Herba Solani Nigri 30 parts, Herba Salviae Chinensis 30 parts, Pseudobulbus Cremastrae Seu Pleiones 30 parts, fries Semen Coicis 30 parts, Herba cassiae occidentalis 30 parts, Rubus Parvifolius L. 30 parts, Herba Duchesneae Indicae 30 parts, Ramulus et folium taxi cuspidatae 3 parts, 10 parts, Radix Glycyrrhizae.
The compound preparation of described treatment advanced lung cancer for guideline with " dialectical+differential diagnosis of diseases+suit the medicine to the illness " treatment, is understood the common TCM Syndrome Type of pulmonary carcinoma by Epidemiological study, in conjunction with its pattern of syndrome, with " disease combination " for guiding theory, is drawn up prescription.In dialectical, adopt retrospective study method, inventor have collected the Guangdong Provincial TCM Hospital cases of lung cancer that in January, 2002 to 2007, year December was in hospital, meet inclusive criteria 435 routine cases are studied, find that qi-asthenia phlegm wet type is maximum, accounting for 76.3%, is secondly type of deficiency of both QI and YIN, the scorchingly hot type of the deficiency of YIN and qi stagnation and blood stasis type; In addition, also carry out analysis to 207 routine patients with terminal pattern of syndrome and find, qi-asthenia phlegm wet type is maximum, is secondly type of deficiency of both QI and YIN, qi stagnation and blood stasis type, the scorchingly hot type of the deficiency of YIN and extreme noxious heat.The TCM Syndrome Type of advanced lung cancer is based on qi-asthenia phlegm wet type, and it is asthenia of pulmonosplenic qi, and pyretic toxicity, phlegm-damp, blood stasis are mark.The present invention, from organic conception determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, dialectically to combine with differential diagnosis of diseases.Dialectical with Radix Codonopsis, the Radix Astragali, the Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae with spleen invigorating lung benefiting, be intended to tonification the foundation of acquired constitution, and have the effect of building up the spleen to supplement the lung, with right supporting anticancer.Differential diagnosis of diseases with Pseudobulbus Cremastrae Seu Pleiones, Herba Hedyotidis Diffusae, Herba Solani Nigri, Herba Salviae Chinensis, Herba Duchesneae Indicae, She Pao le, Semen Coicis (parched), Herba cassiae occidentalis and Ramulus et folium taxi cuspidatae with heat-clearing and toxic substances removing, removing dampness blood stasis dispelling, the anti-tumor of eliminating stagnation.Full side's righting combines with eliminating evil, and differential diagnosis of diseases combines with dialectical.Righting is then paid attention to mending the gas of strengthening spleen and lung, eliminating evil then based on heat-clearing and toxic substances removing, removing dampness eliminating stasis and resolving masses, and the merit of playing right supporting anticancer is altogether share in medicine-feeding, can be widely used in Patients with Advanced Lung Cancer, or has combined attenuation synergistic with Modern medical therapy means and do.
In addition, component choose and in proportioning, inventor is also through demonstration repeatedly and practice, Radix Codonopsis choose with quantitatively on, as adopted Radix Pseudostellariae 30 parts of alternative Radix Codonopsis, but not as good as Radix Codonopsis in effect, reason is, the traditional Chinese medical science is thought for Radix Codonopsis effect is invigorating the spleen and replenishing QI, spleen invigorating lung benefiting; Radix Pseudostellariae tonifying QI to produce body fluid.Thus the current traditional Chinese medical science thinks that Radix Pseudostellariae relatively promotes the production of body fluid, QI invigorating effect is not as Radix Codonopsis; Herba cassiae occidentalis is replaced with Fructus Akebiae, also certain effect can be reached, but from safety guarantee and long-term efficacy, not as good as Herba cassiae occidentalis, because Fructus Akebiae effect liver-smoothing, qi-regulating, promoting blood circulation and stopping pain, Herba cassiae occidentalis subduing swelling and detoxicating, the effect of its subduing swelling and detoxicating is better than Fructus Akebiae, and the pungent loose consumption gas of Fructus Akebiae, tumor patient many merging deficiency of vital energy, prolonged application increases the weight of deficiency of vital energy symptom; Herba Duchesneae Indicae has the effect of subduing swelling and detoxicating, also there is certain antitumor action, from the effect of subduing swelling and detoxicating, Rhizoma Curcumae also can reach this effect, but Rhizoma Curcumae circulation of qi promoting removing blood stasis, patients with lung cancer easily merges spitting of blood, and patients with hemoptysis forbidding Rhizoma Curcumae, thus in the use of reality, Rhizoma Curcumae is also effective not as Herba Duchesneae Indicae; The extract paclitaxel of Ramulus et folium taxi cuspidatae (artificial growth, and process process) has good antitumor action, and therefore the present invention increases Ramulus et folium taxi cuspidatae to strengthen antitumous effect.
The preparation method of the compound preparation of described treatment advanced lung cancer, comprises the following steps:
I. get full dose prescription medical material, add 10-12 times amount water soaking 20-30 minute;
Ii. be heated to boil and decoct 100-120min;
Iii. be separated decocting liquid, medicinal residues continue to decoct with water secondary, add 6-8 times amount soak by water 60min, collecting decoction at every turn;
Iv. decocting liquid concentrate under reduced pressure at low temperature, collects concentrated solution;
I. concentrated solution spraying dry, collects dry powder.
Preferably, in step I, add 12 times amount water soaking 30 minutes.
Preferably, in step I i, decoct 120min.
Preferably, in step I ii, add 8 times of water gagings at every turn and decoct.
This batch every gram dry powder is equivalent to 3.22-6.26 and divides medical material, and dry powder carries out encapsulating.
The compound preparation of described treatment advanced lung cancer is preparing the application in advanced lung cancer medicine.
Beneficial effect of the present invention is:
The compound preparation of described treatment advanced lung cancer of the present invention, has righting and anticancer dual function, especially for the TCM Syndrome Type such as qi-asthenia phlegm wet type, type of deficiency of both QI and YIN that current advanced lung cancer main manifestations goes out, and pointed curative effect; In addition, by the compound preparation of described treatment advanced lung cancer of the present invention, there is Fuzheng-Kang'ai grannule treatment advanced lung cancer and can alleviate patients symptomatic, to make the life better quality, extend the effect of life cycle, combine can improve the quality of living with external high frequency thermotherapy, combine can play attenuation or potentiation with chemotherapy or targeted drug (EGFR-TKI).
The preparation method of the compound preparation of described treatment advanced lung cancer of the present invention, overall process can be completed by machine, easy to prepare, and each manufacturing process is consistent, steady quality.
The application of compound preparation in the medicine preparing advanced lung cancer of described treatment advanced lung cancer of the present invention, has raising drug effect, reduces effect of side effect.
Detailed description of the invention
Below in conjunction with embodiments of the invention, the technical scheme in real to the present invention is clearly and completely described, and obviously, described embodiment is only the present invention's part embodiment, instead of whole embodiments.Based on the embodiment in the present invention, those of ordinary skill in the art, not making the every other embodiment obtained under creative work prerequisite, belong to the scope of protection of the invention.
Embodiment 1
According to formula disclosed by the invention and preparation method, inventor obtains the finished product of embodiment 1 by following process:
Get following component:
Radix Codonopsis 15 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, the Radix Astragali 30 parts, Herba Hedyotidis Diffusae 30 parts, Herba Solani Nigri 30 parts, Herba Salviae Chinensis 30 parts, Pseudobulbus Cremastrae Seu Pleiones 30 parts, fries Semen Coicis 30 parts, Herba cassiae occidentalis 30 parts, Rubus Parvifolius L. 30 parts, Herba Duchesneae Indicae 30 parts, Ramulus et folium taxi cuspidatae 3 parts, 10 parts, Radix Glycyrrhizae.
Adopt following step preparation again:
I. get full dose prescription medical material, add 12 times amount water soaking 30 minutes;
Ii. decoction two hours of boiling is heated to;
Iii. be separated decocting liquid, medicinal residues continue to decoct with water secondary, add 8 times amount soak by water one hour, collecting decoction at every turn;
Iv. decocting liquid concentrate under reduced pressure at low temperature, collects concentrated solution;
V. concentrated solution spraying dry, collects dry powder.
This batch every gram dry powder is equivalent to 6.458 points of medical materials, and dry powder valve bag is distributed into parcel, and every 6 bag complex pocket subpack sealings, obtain the finished product of embodiment 1.
Embodiment 2
Get following each component:
Radix Codonopsis 10 parts, Herba Hedyotidis Diffusae 15 parts, Herba Solani Nigri 15 parts, Herba Salviae Chinensis 15 parts, Pseudobulbus Cremastrae Seu Pleiones 15 parts, Herba cassiae occidentalis 15 parts, Rubus Parvifolius L. 15 parts, Herba Duchesneae Indicae 15 parts, Ramulus et folium taxi cuspidatae 1 part, 5 parts, Radix Glycyrrhizae.
Adopt following step preparation again:
I. get full dose prescription medical material, add 10 times amount water soaking 20 minutes;
Ii. be heated to boil and decoct 100min;
Iii. be separated decocting liquid, medicinal residues continue to decoct with water secondary, add 6 times amount soak by water one hour, collecting decoction at every turn;
Iv. decocting liquid concentrate under reduced pressure at low temperature, collects concentrated solution;
V. concentrated solution spraying dry, collects dry powder.
Dry powder valve bag is distributed into parcel, and every 6 bag complex pocket subpack sealings, obtain the finished product of embodiment 2.
Embodiment 3
Get following component:
Radix Codonopsis 12 parts, the Rhizoma Atractylodis Macrocephalae 12 parts, the Radix Astragali 22 parts, Herba Hedyotidis Diffusae 25 parts, Herba Solani Nigri 20 parts, Herba Salviae Chinensis 20 parts, Pseudobulbus Cremastrae Seu Pleiones 20 parts, fries Semen Coicis 20 parts, Herba cassiae occidentalis 20 parts, Rubus Parvifolius L. 23 parts, Herba Duchesneae Indicae 23 parts, Ramulus et folium taxi cuspidatae 2 parts, 8 parts, Radix Glycyrrhizae.
Adopt following step preparation:
I. get full dose prescription medical material, add 11 times amount water soaking 25 minutes;
Ii. be heated to boil and decoct 110min;
Iii. be separated decocting liquid, medicinal residues continue to decoct with water secondary, add 7 times amount soak by water 60min, collecting decoction at every turn;
Iv. decocting liquid concentrate under reduced pressure at low temperature, collects concentrated solution;
V. concentrated solution spraying dry, collects dry powder.
Dry powder valve bag is distributed into parcel, and every 6 bag complex pocket subpack sealings, obtain the finished product of embodiment 3.
For the therapeutic effect of the compound preparation of this treatment advanced lung cancer, inventors performed for many years, continuous print, multiple experiment, all produce and have positive therapeutic effect, especially at combined with chemotherapy, the aspects such as targeted therapy, the finished product of above 3 embodiments, especially the finished product of most preferred embodiment 1, only represent the section Example in scope disclosed by the invention, instead of whole embodiment, as long as belong to the scope that the present invention openly protects, all at the row of protection, for verifying the treatment of finished product of the present invention, the effect such as auxiliary, inventors performed following experimental demonstration.
Experiment 1
Cell experiment is verified
Observe its effect by the promotion apoptotic effect of compound preparation to Non-small cell lung carcinoma cell strain measuring this treatment advanced lung cancer, data are as following table:
The compound preparation of this treatment advanced lung cancer is to the analytical table of three kinds of Increase Apoptosis of Lung Cancer Cells rates
Wherein:
I. cell A549 is: human lung adenocarcinoma cell; H1650 is: people's pulmonary carcinoma (epidermis) cell; PC9 is: human lung carcinoma cell.
Ii. have employed the finished product proportioning of embodiment 1 in this experiment.
Experiment 2
Variable concentrations cell experiment is verified
The compound preparation measuring various dose finds the promotion apoptotic effect of Non-small cell lung carcinoma cell strain, and along with dosage increases, promote that apoptotic effect is with obvious, data are as following table:
The compound preparation various dose of this treatment advanced lung cancer is to the analytical table of three kinds of Increase Apoptosis of Lung Cancer Cells rates
Wherein:
I. cell A549 is: human lung adenocarcinoma cell; H1650 is: people's pulmonary carcinoma (epidermis) cell; PC9 is: human lung carcinoma cell.
Ii. concentration 1 drug dose: Radix Codonopsis 10 parts, the Rhizoma Atractylodis Macrocephalae 10 parts, the Radix Astragali 15 parts, Herba Hedyotidis Diffusae 15 parts, Herba Solani Nigri 15 parts, Herba Salviae Chinensis 15 parts, Pseudobulbus Cremastrae Seu Pleiones 15 parts, fries Semen Coicis 15 parts, Herba cassiae occidentalis 15 parts, Rubus Parvifolius L. 15 parts, Herba Duchesneae Indicae 15 parts, Ramulus et folium taxi cuspidatae 1 part, 5 parts, Radix Glycyrrhizae.
Iii. concentration 2 drug dose: Radix Codonopsis 10 parts, the Rhizoma Atractylodis Macrocephalae 10 parts, the Radix Astragali 20 parts, Herba Hedyotidis Diffusae 20 parts, Herba Solani Nigri 20 parts, Herba Salviae Chinensis 20 parts, Pseudobulbus Cremastrae Seu Pleiones 20 parts, fries Semen Coicis 20 parts, Herba cassiae occidentalis 20 parts, Rubus Parvifolius L. 20 parts, Herba Duchesneae Indicae 20 parts, Ramulus et folium taxi cuspidatae 2 parts, 5 parts, Radix Glycyrrhizae.
Iv. concentration 3 drug dose: Radix Codonopsis 15 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, the Radix Astragali 30 parts, Herba Hedyotidis Diffusae 30 parts, Herba Solani Nigri 30 parts, Herba Salviae Chinensis 30 parts, Pseudobulbus Cremastrae Seu Pleiones 30 parts, fries Semen Coicis 30 parts, Herba cassiae occidentalis 30 parts, Rubus Parvifolius L. 30 parts, Herba Duchesneae Indicae 30 parts, Ramulus et folium taxi cuspidatae 3 parts, 10 parts, Radix Glycyrrhizae.
Experiment 3
Retrospective analysis shows, the present invention is combined with chemotherapy and can improves Patients with Advanced Lung Cancer life cycle.
Inventor carries out retrospective analysis to the 435 routine patients that in January, 2002 to 2007, year December accepted Chinese medicine (Chinese medicine decoction of more than 80% patient is with modifying a prescription of the present invention) in Guangdong Provincial TCM Hospital oncology, follows up a case by regular visits to on October 30th, 2008.III A phase and before, III B phase, IV phase patient be respectively 83 examples, 160 examples, 192 examples, accounts for 19.1% of all Patients with Non-small-cell Lungs, 36.8%, 44.1% respectively; Histological type is maximum with adenocarcinoma and scale cancer, accounts for 94.5%.435 routine Patients with Non-small-cell Lung 6 months survival rates are 51.0%, 1 year survival rate is 37.0%.Median survival interval is 12.0 months.Traditional Chinese medical science group 6 months survival rates: 39.0%, 1 year survival rate: 25.0%.Median survival time is 8.0 months.Combination of Chinese and Western medicine group 6 months survival rates: 63.0%, 1 year survival rate: 49.0%.Median survival time is 14.0 months.Combination of Chinese and Western medicine group is main combined chemotherapy median survival interval higher than the cisplatin of bibliographical information.
Experiment 4
Adopt early stage the present invention to combine targeted drug treatment advanced Non-small cell lung, show that the present invention has certain synergism and attenuation to targeted drug.
Inventor was in 2009,19 examples are not accepted the patients with advanced NSCLC of other treatment, accept Chinese medicine associating epidermal growth factor recipient tyrosine kinase inhibitor (gefitinib 250mg) treatment, find that the curative effect of the advanced Non-small cell lung of Chinese medicine associating EGFR-TKI first-line treatment EGFR Status unknown is considerable, untoward reaction is very few.After include case in further, advanced NSCLC patients 70 example within 2012, will be included in and carry out interim analysis, 70 routine patients all make a definite diagnosis through histopathology or cytolgical examination, and wherein 49 examples meet the standard of advantage crowd completely, i.e. east ethnic group, women, adenocarcinoma and non smoker; 21 routine those who do not meet, as non-advantage crowd, all accept Fuzheng-Kang'ai grannule, and the compound preparation (250ml, qd) that namely the present invention treats advanced lung cancer combines gefitinib (250mg, qd) treatment.
This experimental result:
CR 0 example in 49 routine advantage crowd patients, reach PR 16 example (32.7%), SD 30 example (61.2%), PD3 example (6.1%), ORR is 32.7%, DCR is 93.9%; Meta progressive free life span (PFS) 8.2 months, median survival interval 9.9 months after treatment.CR 0 example in 21 routine non-advantage crowd patients, reach PR 5 example (23.8%), SD 9 example (42.9%), PD 7 example (33.3%), ORR is 23.8%, DCR is 66.7%; Meta progressive free life span (PFS) 4.6 months, median survival interval 7.9 months after treatment.The two has significant difference.During first-line treatment, the objective remission rate of advantage crowd and non-advantage crowd is consistent, is 21.4%.Toxicity is comparatively light, toleration can, major part is 1 ~ 2 grade, and remission after symptomatic treatment, does not affect treatment.The curative effect of anticancer " Fuzheng Decoction associating gefitinib in treatment nonsmall-cell lung cancer advantage crowd is better than non-advantage crowd.
The foregoing is only preferred embodiment of the present invention, not in order to limit the present invention, within the spirit and principles in the present invention all, any amendment done, equivalent replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (8)
1. treat the compound preparation of advanced lung cancer for one kind, it is characterized in that, comprise each component of following weight portion: Radix Codonopsis 10-15 part, Herba Hedyotidis Diffusae 15-30 part, Herba Solani Nigri 15-30 part, Herba Salviae Chinensis 15-30 part, Pseudobulbus Cremastrae Seu Pleiones 15-30 part, Herba cassiae occidentalis 15-30 part, Rubus Parvifolius L. 15-30 part, Herba Duchesneae Indicae 15-30 part, Ramulus et folium taxi cuspidatae 1-3 part, Radix Glycyrrhizae 5-10 part.
2. treat a compound preparation for advanced lung cancer, it is characterized in that, comprise each component of following weight portion: Radix Codonopsis 10-15 part, Rhizoma Atractylodis Macrocephalae 10-15 part, Radix Astragali 15-30 part, Herba Hedyotidis Diffusae 15-30 part, Herba Solani Nigri 15-30 part, Herba Salviae Chinensis 15-30 part, Pseudobulbus Cremastrae Seu Pleiones 15-30 part, fry Semen Coicis 15-30 part, Herba cassiae occidentalis 15-30 part, Rubus Parvifolius L. 15-30 part, Herba Duchesneae Indicae 15-30 part, Ramulus et folium taxi cuspidatae 1-3 part, Radix Glycyrrhizae 5-10 part.
3. treat a compound preparation for advanced lung cancer, it is characterized in that, comprise each component of following weight portion: Radix Codonopsis 15 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, the Radix Astragali 30 parts, Herba Hedyotidis Diffusae 30 parts, Herba Solani Nigri 30 parts, Herba Salviae Chinensis 30 parts, Pseudobulbus Cremastrae Seu Pleiones 30 parts, fry Semen Coicis 30 parts, Herba cassiae occidentalis 30 parts, Rubus Parvifolius L. 30 parts, Herba Duchesneae Indicae 30 parts, Ramulus et folium taxi cuspidatae 3 parts, 10 parts, Radix Glycyrrhizae.
4., as the preparation method of the compound preparation for the treatment of advanced lung cancer as described in arbitrary in claim 1-3, it is characterized in that, comprise the following steps:
I. get full dose prescription medical material, add 10-12 times amount water soaking 20-30 minute;
Ii. be heated to boil and decoct 100-120min;
Iii. be separated decocting liquid, medicinal residues continue to decoct with water secondary, add 6-8 times amount soak by water 60min, collecting decoction at every turn;
Iv. decocting liquid concentrate under reduced pressure at low temperature, collects concentrated solution;
V. concentrated solution spraying dry, collects dry powder.
5. treat the preparation method of the compound preparation of advanced lung cancer as claimed in claim 4, it is characterized in that:
In step I, add 12 times amount water soaking 30 minutes.
6. treat the preparation method of the compound preparation of advanced lung cancer as claimed in claim 4, it is characterized in that:
In step I i, decoct 120min.
7. treat the preparation method of the compound preparation of advanced lung cancer as claimed in claim 4, it is characterized in that:
In step I ii, add 8 times of water gagings at every turn and decoct.
8. as the compound preparation for the treatment of advanced lung cancer as described in arbitrary in claim 1-3 is preparing the application in advanced lung cancer medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410660448.6A CN104306807A (en) | 2014-11-18 | 2014-11-18 | Compound preparation for treating advanced lung cancer and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410660448.6A CN104306807A (en) | 2014-11-18 | 2014-11-18 | Compound preparation for treating advanced lung cancer and preparing method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104306807A true CN104306807A (en) | 2015-01-28 |
Family
ID=52362216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410660448.6A Pending CN104306807A (en) | 2014-11-18 | 2014-11-18 | Compound preparation for treating advanced lung cancer and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104306807A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107875311A (en) * | 2017-12-05 | 2018-04-06 | 山东大学齐鲁医院 | A kind of mitigation targeted therapy side reaction, the medicine of auxiliary treatment lung cancer |
| CN107875283A (en) * | 2017-12-05 | 2018-04-06 | 山东大学齐鲁医院 | A kind of Chinese medicine compound prescription for treating lung cancer and preparation method thereof |
| CN112138066A (en) * | 2020-09-09 | 2020-12-29 | 中南大学湘雅医院 | Application of black nightshade or black nightshade extract in increasing antibiotic or antineoplastic drug sensitivity |
| CN113648394A (en) * | 2021-09-14 | 2021-11-16 | 关晓仪 | Anticancer traditional Chinese medicine combination extract, single medicine extract composition and application |
| CN115957285A (en) * | 2022-12-09 | 2023-04-14 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | A Chinese medicinal granule for treating lung cancer |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316249A (en) * | 2012-03-23 | 2013-09-25 | 黑龙江久久药业有限责任公司 | Astragalus taxus chinensis capsule and preparing process thereof |
| CN103611003A (en) * | 2013-11-22 | 2014-03-05 | 杨兆辉 | Traditional Chinese medicine composition for improving somatic functions of patients with lung cancer and preparation method thereof |
-
2014
- 2014-11-18 CN CN201410660448.6A patent/CN104306807A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316249A (en) * | 2012-03-23 | 2013-09-25 | 黑龙江久久药业有限责任公司 | Astragalus taxus chinensis capsule and preparing process thereof |
| CN103611003A (en) * | 2013-11-22 | 2014-03-05 | 杨兆辉 | Traditional Chinese medicine composition for improving somatic functions of patients with lung cancer and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 吴万垠: "中医药在恶性肿瘤治疗中的"替代"与"补充"作用", 《中国中西医结合杂志》 * |
| 王云凯等: "《新编中医学》", 30 November 1996 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107875311A (en) * | 2017-12-05 | 2018-04-06 | 山东大学齐鲁医院 | A kind of mitigation targeted therapy side reaction, the medicine of auxiliary treatment lung cancer |
| CN107875283A (en) * | 2017-12-05 | 2018-04-06 | 山东大学齐鲁医院 | A kind of Chinese medicine compound prescription for treating lung cancer and preparation method thereof |
| CN112138066A (en) * | 2020-09-09 | 2020-12-29 | 中南大学湘雅医院 | Application of black nightshade or black nightshade extract in increasing antibiotic or antineoplastic drug sensitivity |
| CN113648394A (en) * | 2021-09-14 | 2021-11-16 | 关晓仪 | Anticancer traditional Chinese medicine combination extract, single medicine extract composition and application |
| CN113648394B (en) * | 2021-09-14 | 2022-08-02 | 关晓仪 | Anticancer traditional Chinese medicine combination extract, single medicine extract composition and application |
| CN115957285A (en) * | 2022-12-09 | 2023-04-14 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | A Chinese medicinal granule for treating lung cancer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104306807A (en) | Compound preparation for treating advanced lung cancer and preparing method thereof | |
| CN103768523A (en) | Chinese herbal medicine compound preparation for treating malignant tumors and preparation method of compound preparation | |
| CN104524383A (en) | Traditional Chinese medicine for silicosis treating | |
| CN105878938A (en) | Pharmaceutical preparation for treating lung cancer and application thereof | |
| CN106377535A (en) | A ginsenoside composition, a preparing method thereof and applications of the ginsenoside composition | |
| CN105395989A (en) | Chinese medicinal preparation for treatment of lung cancer, preparation method and application thereof | |
| CN102247479A (en) | Antitumor strong medicine and preparation method thereof | |
| CN103330821A (en) | Traditional Chinese medicine for treating chest stuffiness and heart pain | |
| CN103550718B (en) | A kind of Chinese medicine composition for the treatment of pulmonary carcinoma | |
| CN102688447B (en) | Traditional Chinese medicine for treating palpitation and cardiac pain, and preparation method thereof | |
| CN105434577A (en) | Traditional Chinese medicine preparation for treating advanced lung cancer and preparation method and application thereof | |
| CN102940871B (en) | Chinese medicament for treating chronic hepatitis | |
| CN102872385B (en) | Compound Chinese medicinal composition for treating advanced gastric cancer and preparation method and application thereof | |
| CN101954034B (en) | Chinese medicinal preparation for treating acquired immune deficiency syndrome and preparation method thereof | |
| CN104257883A (en) | Traditional Chinese medicine composition for treating leucopenia after chemotherapy | |
| CN103933430A (en) | Chronic hepatitis B drug and preparation method thereof | |
| CN106902307A (en) | A kind of Chinese medicine composition and usage for treating malignant tumor of lung | |
| CN105327189A (en) | Traditional Chinese medicine preparation for treating laryngeal cancer and preparation method and application thereof | |
| CN104857151A (en) | Traditional Chinese medicine for treating primary liver cancer | |
| CN104491318A (en) | Traditional Chinese preparation used for treating asthma and preparation method of traditional Chinese preparation | |
| CN104306847A (en) | Six-ingredient qi-tonifying capsule and preparation process thereof | |
| CN108686157A (en) | A kind of Chinese medicine composition, preparation method and the pharmaceutical preparation of prevention type of stagnation of blood stasis breast addiction | |
| CN102772763B (en) | Traditional Chinese medicinal composition for resisting tumor metastasis and method for preparing traditional Chinese medicinal composition | |
| CN104324041A (en) | Novel compound medicine for auxiliary treatments on liver cancer | |
| CN102302718B (en) | Antitumor medicinal composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150128 |
|
| WD01 | Invention patent application deemed withdrawn after publication |